# Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older

> **NCT06686654** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 1530 (actual)

## Conditions studied

- Human Metapneumovirus Immunization
- Respiratory Syncytial Virus Immunization

## Interventions

- **BIOLOGICAL:** Investigational hMPV/RSV vaccine
- **BIOLOGICAL:** Investigational hMPV vaccine (monovalent)
- **BIOLOGICAL:** Investigational RSV vaccine (monovalent)
- **BIOLOGICAL:** Licensed RSV Vaccine
- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** Investigational RSV+hMPV vaccine

## Key facts

- **NCT ID:** NCT06686654
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-11-11
- **Primary completion:** 2027-01-18
- **Final completion:** 2027-01-18
- **Target enrollment:** 1530 (ACTUAL)
- **Last updated:** 2025-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06686654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06686654, "Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06686654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*